BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 35511697)

  • 1. Identification of patients with branch-duct intraductal papillary mucinous neoplasm and very low risk of cancer: multicentre study.
    Tamburrino D; de Pretis N; Pérez-Cuadrado-Robles E; Uribarri-Gonzalez L; Ateeb Z; Belfiori G; Maisonneuve P; Capurso G; Vanella G; Petrone MC; Arcidiacono PG; Vaalavuo Y; Frulloni L; Dominguez-Muñoz JE; Deprez PH; Falconi M; Del Chiaro M; Crippa S; Laukkarinen J
    Br J Surg; 2022 Jun; 109(7):617-622. PubMed ID: 35511697
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term follow-up of branch-duct intraductal papillary mucinous neoplasms with No change in first 5 Years of diagnosis.
    Lee BS; Nguyen AK; Tekeste TF; Chang K; Girgis A; Adeyemo M; Hanna MS; Yao JF; Kwok KK; Giap AQ; Hunt GC; Chaya CT; Kao KT; Attam R; Ko A; Pio JR; Tovar S; Lim BS
    Pancreatology; 2021 Jan; 21(1):144-154. PubMed ID: 33309223
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term surveillance of branch-duct intraductal papillary mucinous neoplasms without worrisome or high-risk features.
    Lattimore CM; Kane WJ; Subbarao S; Venitti C; Cramer CL; Turkheimer LM; Bauer TW; Turrentine FE; Zaydfudim VM
    J Surg Oncol; 2023 Dec; 128(7):1087-1094. PubMed ID: 37530526
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of high-risk stigmata and worrisome features with advanced neoplasia in intraductal papillary mucinous neoplasms (IPMN): A systematic review.
    Ohno E; Balduzzi A; Hijioka S; De Pastena M; Marchegiani G; Kato H; Takenaka M; Haba S; Salvia R
    Pancreatology; 2024 Feb; 24(1):48-61. PubMed ID: 38161091
    [TBL] [Abstract][Full Text] [Related]  

  • 5. "Trivial" Cysts Redefine the Risk of Cancer in Presumed Branch-Duct Intraductal Papillary Mucinous Neoplasms of the Pancreas: A Potential Target for Follow-Up Discontinuation?
    Marchegiani G; Andrianello S; Pollini T; Caravati A; Biancotto M; Secchettin E; Bonamini D; Malleo G; Bassi C; Salvia R
    Am J Gastroenterol; 2019 Oct; 114(10):1678-1684. PubMed ID: 31449158
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Active Surveillance Beyond 5 Years Is Required for Presumed Branch-Duct Intraductal Papillary Mucinous Neoplasms Undergoing Non-Operative Management.
    Crippa S; Pezzilli R; Bissolati M; Capurso G; Romano L; Brunori MP; Calculli L; Tamburrino D; Piccioli A; Ruffo G; Fave GD; Falconi M
    Am J Gastroenterol; 2017 Jul; 112(7):1153-1161. PubMed ID: 28244498
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A retrospective study of intraductal papillary neoplasia of the pancreas (IPMN) under surveillance.
    Johansson K; Kaprio T; Nieminen H; Lehtimäki TE; Lantto E; Haglund C; Seppänen H
    Scand J Surg; 2022; 111(1):14574969221076792. PubMed ID: 35333109
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Branch duct-intraductal papillary mucinous neoplasms (BD-IPMNs): an MRI-based radiomic model to determine the malignant degeneration potential.
    Flammia F; Innocenti T; Galluzzo A; Danti G; Chiti G; Grazzini G; Bettarini S; Tortoli P; Busoni S; Dragoni G; Gottin M; Galli A; Miele V
    Radiol Med; 2023 Apr; 128(4):383-392. PubMed ID: 36826452
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pancreatic fat content may increase the risk of imaging progression in low-risk branch duct intraductal papillary mucinous neoplasm.
    Kashiwagi K; Minami K; Seino T; Hirata K; Iwasaki E; Inoue N; Iwao Y; Kanai T
    J Dig Dis; 2019 Oct; 20(10):557-562. PubMed ID: 31322828
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Systematic review on surveillance for non-resected branch-duct intraductal papillary mucinous neoplasms of the pancreas.
    Kazmi SZ; Jung HS; Han Y; Yun WG; Cho YJ; Lee M; Kwon W; Castillo CF; Del Chiaro M; Marchegiani G; Goh BKP; Hijioka S; Majumder S; Nakai Y; Shin A; Jang JY
    Pancreatology; 2024 May; 24(3):463-488. PubMed ID: 38480047
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of efficacy of pancreatic juice cytology for risk classification according to international consensus guidelines in patients with intraductal papillary mucinous neoplasm; a retrospective study.
    Yamakawa K; Masuda A; Nakagawa T; Shiomi H; Toyama H; Takenaka M; Sakai A; Kobayashi T; Tsujimae M; Ashina S; Yamada Y; Tanaka T; Tanaka S; Nakano R; Sato Y; Ikegawa T; Kurosawa M; Fujigaki S; Kutsumi H; Itoh T; Fukumoto T; Kodama Y
    Pancreatology; 2019 Apr; 19(3):424-428. PubMed ID: 30857854
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimal Surveillance Interval of Branch Duct Intraductal Papillary Mucinous Neoplasm of the Pancreas.
    Han Y; Kwon W; Lee M; Jung HS; Yun WG; Cho YJ; Chae YS; Fernández-Del Castillo C; Marchegiani G; Salvia R; Goh BKP; Lee WJ; Jang JY
    JAMA Surg; 2024 Apr; 159(4):389-396. PubMed ID: 38231494
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk Factors for the Development of High-risk Stigmata in Branch-duct Intraductal Papillary Mucinous Neoplasms.
    Yamazaki T; Tomoda T; Kato H; Miyamoto K; Matsumi A; Ueta E; Fujii Y; Saragai Y; Uchida D; Matsumoto K; Horiguchi S; Tsutsumi K; Okada H
    Intern Med; 2021 Oct; 60(20):3205-3211. PubMed ID: 33967138
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of branch-duct intraductal papillary mucinous neoplasms of the pancreas: state of the art.
    Crippa S; Piccioli A; Salandini MC; Cova C; Aleotti F; Falconi M
    Updates Surg; 2016 Sep; 68(3):265-271. PubMed ID: 27502606
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Surveillance for Presumed BD-IPMN of the Pancreas: Stability, Size, and Age Identify Targets for Discontinuation.
    Marchegiani G; Pollini T; Burelli A; Han Y; Jung HS; Kwon W; Rocha Castellanos DM; Crippa S; Belfiori G; Arcidiacono PG; Capurso G; Apadula L; Zaccari P; Noia JL; Gorris M; Busch O; Ponweera A; Mann K; Demir IE; Phillip V; Ahmad N; Hackert T; Heckler M; Lennon AM; Afghani E; Vallicella D; Dall'Olio T; Nepi A; Vollmer CM; Friess H; Ghaneh P; Besselink M; Falconi M; Bassi C; Goh BK; Jang JY; Fernández-Del Castillo C; Salvia R
    Gastroenterology; 2023 Oct; 165(4):1016-1024.e5. PubMed ID: 37406887
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Can the location of the mural nodule indicate benign or malignant in branch duct-type intraductal papillary mucinous neoplasm of the pancreas?
    Niiya F; Ohike N; Norose T; Takano Y; Azami T; Kobayashi T; Maruoka N; Wakabayashi T; Matsuo K; Tanaka K; Nagahama M
    Pancreatology; 2020 Oct; 20(7):1379-1385. PubMed ID: 32873485
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term Risk of Pancreatic Malignancy in Patients With Branch Duct Intraductal Papillary Mucinous Neoplasm in a Referral Center.
    Pergolini I; Sahora K; Ferrone CR; Morales-Oyarvide V; Wolpin BM; Mucci LA; Brugge WR; Mino-Kenudson M; Patino M; Sahani DV; Warshaw AL; Lillemoe KD; Fernández-Del Castillo C
    Gastroenterology; 2017 Nov; 153(5):1284-1294.e1. PubMed ID: 28739282
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The safety and benefit of pancreatic juice cytology under ERCP in IPMN patients.
    Yoshioka T; Shigekawa M; Yamai T; Suda T; Kegasawa T; Iwahashi K; Ikezawa K; Sakamori R; Yakushijin T; Hiramatsu N; Tatsumi T; Takehara T
    Pancreatology; 2016; 16(6):1020-1027. PubMed ID: 27567445
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Management of branch-duct intraductal papillary mucinous neoplasms: a large single-center study to assess predictors of malignancy and long-term outcomes.
    Ridtitid W; DeWitt JM; Schmidt CM; Roch A; Stuart JS; Sherman S; Al-Haddad MA
    Gastrointest Endosc; 2016 Sep; 84(3):436-45. PubMed ID: 26905937
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Progression of Pancreatic Branch Duct Intraductal Papillary Mucinous Neoplasm Associates With Cyst Size.
    Han Y; Lee H; Kang JS; Kim JR; Kim HS; Lee JM; Lee KB; Kwon W; Kim SW; Jang JY
    Gastroenterology; 2018 Feb; 154(3):576-584. PubMed ID: 29074452
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.